# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN-TD
- Date: 2008-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of home blood pressure readings, with liver elastography, ultrasound and hepatology. **S**

## History of present illness

Mr. Frazier returns two weeks after intake with a week of home blood pressure readings, twice a day, averaging 146/90. He is taking metformin, lisinopril and the new atorvastatin without trouble. This morning he had liver elastography and a liver ultrasound, and he saw Dr. Deshpande of hepatology. He has had no swelling of the legs or abdomen, no black stools, no confusion and no yellowing. He drinks one or two beers on some weekends and agreed today to stop. He asked what a scarred liver means for his work at the gym. **S**

| Element | Detail |
|---|---|
| Home blood pressure | Average 146/90 over seven days |
| Atorvastatin | Two weeks; no muscle aches |
| Liver symptoms | None |
| Alcohol | Agreed to stop |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Negative | No abdominal swelling, black stools or vomiting of blood |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Neurological | Negative | No confusion or day-night reversal |

3 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years **S**
- Lisinopril 20 mg oral tablet, one tablet daily; taken for years **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- Amlodipine 5 mg oral tablet, one tablet daily **S**
- Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/90 mmHg; pulse 74 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 103.6 kg; BMI 31.3 kg/m². All vital signs are synthetic.

Liver stiffness (transient elastography): 17.6 kPa (high); INR: 1.1; Alpha-fetoprotein (AFP): 4.2 ng/mL. All results are synthetic.

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**
- Hepatitis B vaccine (HepB-CpG), dose 1 of 2 **S**
- Hepatitis A vaccine, adult, dose 1 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 148/90, pulse 74; weight 103.6 kg |
| Abdomen | Soft; liver edge firm at the costal margin; spleen tip not felt; no ascites |
| Skin | No jaundice, spider angiomas or palmar erythema |
| Neurological | No asterixis |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Compensated cirrhosis from MASLD** (K74.69). Liver stiffness 17.6 kPa with a controlled attenuation parameter of 318 dB/m; ultrasound shows a mildly nodular liver, a spleen of 13.4 cm and no focal lesion; AFP 4.2 ng/mL; INR 1.1; albumin 4.0 g/dL; bilirubin 0.9 mg/dL; platelets 138. Child-Pugh A (5 points), MELD 8. Hepatitis B surface antigen, core antibody and surface antibody negative; hepatitis A antibody negative; hepatitis C antibody and HIV test nonreactive; iron studies and autoimmune tests normal. Dr. Deshpande agrees this is compensated cirrhosis from MASLD, with little alcohol. **S**
   - Liver ultrasound with AFP every six months; the next in September.
   - Upper endoscopy to screen for varices, because platelets below 150 and a stiffness of 17.6 kPa cannot rule out portal hypertension.
   - No alcohol; no ibuprofen or naproxen; acetaminophen no more than 2 g a day.
   - PCV20 and first doses of hepatitis A and B vaccines today.
2. **Type 2 diabetes, A1c 8.4%** (E11.65). Above goal on metformin. A GLP-1 receptor agonist adds cardiovascular and kidney benefit and helps weight and steatotic liver disease; it is safe in compensated cirrhosis. Coverage approved after prior authorization. **S**
   - Start semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly.
   - Continue metformin, safe with normal kidney function and compensated cirrhosis.
   - Diabetes self-management class booked.
3. **Hypertension** (I10). Home average 146/90 confirms blood pressure above the goal of 130/80 on lisinopril. **S**
   - Add amlodipine 5 mg daily.
   - Home readings twice a day for a week before the next visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (clinic and home), weight and BMI | Every visit | Completed today | 148/90 in the clinic; home average 146/90; weight 103.6 kg |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal or after a change in treatment, then every 6 months | Up to date | 8.4% two weeks ago; next in three months |
| Medication safety | Low blood sugar review and medicine tolerability | Every visit | Completed today | No low blood sugar; metformin tolerated |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Up to date | Atorvastatin started two weeks ago; lipids at eight weeks |
| Laboratory | Potassium, creatinine and eGFR (CKD-EPI 2003) on lisinopril | Every 6 months on an ACE inhibitor, and after changes | Up to date | Potassium 4.6, creatinine 1.08 mg/dL, eGFR 77 two weeks ago |
| Laboratory | Urine albumin-to-creatinine ratio | Yearly | Up to date | 18 mg/g two weeks ago |
| Laboratory | Liver tests with FIB-4 | Yearly with diabetes; FIB-4 1.3 or higher leads to elastography | Up to date | FIB-4 3.43 two weeks ago (age 64, AST 48, ALT 42, platelets 138): high risk |
| Imaging | Transient elastography | When FIB-4 is 1.3 or higher; repeat in 1 to 2 years | Completed today | Liver stiffness 17.6 kPa; controlled attenuation parameter 318 dB/m |
| Imaging | Liver ultrasound with AFP for hepatocellular carcinoma surveillance | Every 6 months in cirrhosis | Completed today | Baseline ultrasound without a focal lesion; AFP 4.2 ng/mL |
| Laboratory | Liver function (albumin, bilirubin, INR, platelets; Child-Pugh and MELD) | At diagnosis, then every 6 months | Completed today | INR 1.1, albumin 4.0, bilirubin 0.9, platelets 138; Child-Pugh A5, MELD 8 |
| Referral | Variceal screening | Endoscopy when portal hypertension cannot be ruled out; repeat in 2 years if no varices and the liver injury continues | Ordered | Upper endoscopy booked for next month |
| Self-management | Alcohol abstinence | Every visit | Completed today | Agreed to stop the occasional beer |
| Self-management | No NSAIDs; acetaminophen no more than 2 g a day | Every visit | Completed today | Explained; he uses no pain medicine now |
| Self-management | Vaccines for diabetes and chronic liver disease | At diagnosis of chronic liver disease | Completed today | PCV20 and first doses of hepatitis A and B vaccines today |
| Referral | Hepatology consultation | At diagnosis of advanced fibrosis or cirrhosis | Completed today | Seen by Dr. Deshpande today |
| Self-management | Medicine cost and coverage | With each new medicine | Completed today | Semaglutide approved after prior authorization; generics for the rest |

## Goal progress

- A1c below 7% within six to nine months, without low blood sugar. In progress; target 2008-09-14. **S**
- Blood pressure below 130/80 mmHg in the clinic and at home. In progress; target 2008-09-14. **S**
- LDL cholesterol below 70 mg/dL. In progress; target 2008-04-13. **S**
- Weight loss of 7 to 10% for liver health within a year. In progress; target 2008-09-14. **S**
- Liver cancer surveillance by ultrasound with AFP every six months, on time. In progress; target 2008-09-14. **S**
- No alcohol, to protect the liver. In progress; target 2008-09-14. **S**

## Medication changes

- Started: Amlodipine 5 mg oral tablet, one tablet daily **S**
- Started: Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly **S**

## Guideline basis

- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023), American Association for the Study of Liver Diseases (Hepatology 2023;77(5))
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023), American Association for the Study of Liver Diseases (Hepatology 2023;78(6))
- Baveno VII - Renewing consensus in portal hypertension (2022), Baveno VII Faculty (Journal of Hepatology 2022;76(4))
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Endoscopy next month. Visit in six weeks with lipids, potassium, creatinine and home readings. Diabetes class. **S**
- Next scheduled visit 2008-04-13: eight-week review: blood pressure, lipids, kidney function, semaglutide, the endoscopy result and vaccines. **S**
